Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission and Apoptosis Research

Executive Summary: Mdivi-1 (SKU A4472, APExBIO) is a selective, cell-permeable inhibitor of mitochondrial division dynamin-related GTPase 1 (DRP1), used to block mitochondrial fission in vitro and in vivo ([Li et al., 2025](https://doi.org/10.1016/j.bbadis.2025.167720)). At 50 μM, Mdivi-1 inhibits DRP1 self-assembly and reduces apoptosis in mammalian cells as measured by annexin V staining ([APExBIO product docs](https://www.apexbt.com/mdivi-1.html)). In C57BL/6 mice, intraperitoneal Mdivi-1 (50 mg/kg) increases retinal ganglion cell survival post-ischemia without affecting blood pressure or behavior ([APExBIO](https://www.apexbt.com/mdivi-1.html)). The compound is highly insoluble in water/ethanol but dissolves to ≥17.65 mg/mL in DMSO. Mdivi-1’s utility spans apoptosis assay development, neuroprotection, and mitochondrial dynamics research ([Li et al., 2025](https://doi.org/10.1016/j.bbadis.2025.167720)).

Biological Rationale

Mitochondrial fission and fusion regulate mitochondrial morphology, bioenergetics, and cellular fate. Dynamin-related GTPase 1 (DRP1) orchestrates mitochondrial division, a process critical for cell proliferation, apoptosis, and adaptation to metabolic stress ([Li et al., 2025](https://doi.org/10.1016/j.bbadis.2025.167720)). Excessive DRP1-mediated fission is implicated in neurodegeneration, ischemic injury, and vascular remodeling. Inhibition of DRP1 function with small molecules such as Mdivi-1 enables precise dissection of mitochondrial events in diverse research contexts. Mdivi-1 is particularly relevant for studies of apoptosis, as mitochondrial fission often precedes cytochrome c release and caspase activation. Its specificity for DRP1 makes it a valuable probe in both basic and translational models, including hypoxia-induced pulmonary hypertension and ischemic retinal injury.

Mechanism of Action of Mdivi-1

Mdivi-1 selectively inhibits the GTPase activity of DRP1, blocking its ability to self-assemble and constrict mitochondrial membranes ([APExBIO](https://www.apexbt.com/mdivi-1.html)). By impeding DRP1 function, Mdivi-1 prevents mitochondrial division and fragmentation, maintaining mitochondrial integrity under stress. Mechanistically, Mdivi-1 disrupts Bid-activated Bax/Bak-dependent cytochrome c release, thus attenuating the intrinsic (mitochondrial) apoptosis pathway. This effect is quantifiable in vitro by reduced annexin V and caspase activity. In vivo, Mdivi-1 demonstrates neuroprotective effects by preserving mitochondrial morphology and reducing glial fibrillary acidic protein (GFAP) expression after ischemic injury. This distinguishes it from non-selective mitochondrial disruptors.

Evidence & Benchmarks

• Mdivi-1 at 50 μM blocks DRP1 self-assembly and mitochondrial fission in mammalian cells, reducing apoptotic markers such as annexin V positivity (APExBIO).
• Intraperitoneal injection of Mdivi-1 (50 mg/kg) in C57BL/6 mice increases retinal ganglion cell survival post-ischemia, with no systemic toxicity observed (APExBIO).
• In hypoxia-induced pulmonary hypertension models, Mdivi-1 reverses smooth muscle cell proliferation by inhibiting DRP1 in the context of ADAM10-PI3K/AKT/mTOR pathway activation (Li et al., 2025).
• Mdivi-1 is insoluble in water and ethanol, but dissolves to ≥17.65 mg/mL in DMSO; optimal solubility is achieved by warming at 37°C or using ultrasonic bath treatment (APExBIO).
• Stock solutions of Mdivi-1 are stable below -20°C for several months; avoid prolonged storage at room temperature or in solution (APExBIO).

Applications, Limits & Misconceptions

Applications:

• Apoptosis assays in mammalian and yeast cells to probe mitochondrial outer membrane permeabilization.
• Neuroprotection studies in ischemic retinal injury and neurodegeneration models.
• Mitochondrial dynamics research, including fission/fusion assays and live-cell imaging.
• Exploration of caspase-independent apoptosis pathways and cell survival mechanisms.

This article extends the scenario-driven workflow analysis in Mdivi-1 (SKU A4472): Scenario-Driven Solutions for Mitoch... by presenting new quantitative benchmarks and clarifying the molecular mechanism via recently published data.

For further protocol optimization, see Mdivi-1 (SKU A4472): Scenario-Driven Solutions for Mitoch..., which this article updates by integrating evidence for in vivo neuroprotection and highlighting storage/solubility best practices.

To explore broader comparative insights and translational opportunities, contrast with Mdivi-1: Unraveling Selective DRP1 Inhibition in Apoptosi..., noting this article’s focus on quantitative benchmarks and the ADAM10-DRP1 axis in disease models.

Common Pitfalls or Misconceptions

• Mdivi-1 is not soluble in water or ethanol; improper dissolution leads to precipitation and reduced activity (APExBIO).
• Long-term storage of Mdivi-1 solutions at room temperature degrades potency; always store at <-20°C.
• Mdivi-1 is selective for DRP1 but does not inhibit other dynamin family GTPases.
• Not suitable for experiments requiring aqueous delivery unless first dissolved in DMSO or other compatible solvents.
• Off-target effects at concentrations >50 μM have not been systematically excluded in all cell types.

Workflow Integration & Parameters

Mdivi-1 is supplied as a solid and should be stored at -20°C for maximum stability. For experimental use, dissolve in DMSO to a concentration of ≥17.65 mg/mL, warming gently at 37°C or using an ultrasonic bath. Working concentrations for in vitro assays typically range from 10–50 μM. For in vivo use, validated protocols employ 50 mg/kg administered intraperitoneally in C57BL/6 mice. Avoid aqueous buffers as primary solvents. Stock solutions can be stored below -20°C for several months, minimizing freeze-thaw cycles. The use of Mdivi-1 in apoptosis, mitochondrial fission, and neuroprotection workflows enables reproducible, interpretable results when integrated with standard viability and imaging assays. For further scenario-based protocol guidance, refer to Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fissi..., noting that this article updates solubility and storage recommendations.

Conclusion & Outlook

Mdivi-1, as offered by APExBIO, is a validated, selective DRP1 inhibitor with high utility in mitochondrial dynamics research, apoptosis assays, and in vivo neuroprotection studies. Its robust performance, when correctly solubilized and handled, supports its role as a gold standard tool for dissecting mitochondrial fission and cell fate decisions. Future research may address off-target activity in additional disease models and expand indications through combination with pathway-specific inhibitors.